The Relevance of Testing the Efficacy of Anti-Angiogenesis Treatments on Cells Derived from Primary Tumors: A New Method for the Personalized Treatment of Renal Cell Carcinoma

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model

(2015) Libo Zhang et al.   NEOPLASIA

Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial  5 Integrin

(2013) Y. Cao et al.   CANCER RESEARCH

Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches

(2013) Bruno Bockorny et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

(2013) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Therapy for Kidney Cancer: A Second Dawn?

(2013) David F. McDermott et al.   SEMINARS IN ONCOLOGY

Renal Cell Carcinoma With Clear Cell and Papillary Features

(2012) Hillary Ross et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

VEGF Exerts an Angiogenesis-Independent Function in Cancer Cells to Promote Their Malignant Progression

(2012) Ying Cao et al.   CANCER RESEARCH

BRAF Mutations in Metanephric Adenoma of the Kidney

(2012) Toni K. Choueiri et al.   EUROPEAN UROLOGY

Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm

(2012) S. K. Pal et al.   MOLECULAR CANCER THERAPEUTICS

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma

(2012) S. Sivanand et al.   Science Translational Medicine

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

(2011) K. J. Gotink et al.   CLINICAL CANCER RESEARCH

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines

(2011) R Grepin et al.   ONCOGENE

Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies

(2011) A. Ravaud   ONCOLOGIST

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network

(2010) G. G. Malouf et al.   ANNALS OF ONCOLOGY

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

(2010) K. Yu et al.   CANCER RESEARCH

Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma

(2010) I. J. Davis et al.   CANCER RESEARCH

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma

(2010) Jose A. Karam et al.   EUROPEAN UROLOGY

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

(2010) Christophe Ginestier et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis

(2010) Fanny Burel-Vandenbos et al.   JOURNAL OF NEURO-ONCOLOGY

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

(2010) H. J. Hammers et al.   MOLECULAR CANCER THERAPEUTICS

Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature

(2009) Henry B Armah et al.   Diagnostic Pathology

The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21WAF1/CIP1-mediated cell cycle delay

(2009) Klaas Medendorp et al.   EXPERIMENTAL CELL RESEARCH

The role of CXC chemokines and their receptors in cancer

(2008) Jo Vandercappellen et al.   CANCER LETTERS

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

(2008) Valeria Facchinetti et al.   EMBO JOURNAL

Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion

(2008) J. Müller-Höcker et al.   PATHOLOGY RESEARCH AND PRACTICE